Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-361: Pembrolizumab +/- Chemo in Advanced Urothelial Carcinoma
NCT02853305Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2016
- Primary completion
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in urothelial carcinoma (UC), sponsored by Merck & Co.. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02853305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02853305.